Next Article in Journal
Modulation of TRP Channel Activity by Hydroxylation and Its Therapeutic Potential
Next Article in Special Issue
Development of a Glycosaminoglycan Derived, Selectin Targeting Anti-Adhesive Coating to Treat Endothelial Cell Dysfunction
Previous Article in Journal
An Updated View on an Emerging Target: Selected Papers from the 8th International Conference on Protein Kinase CK2
Article Menu
Issue 2 (June) cover image

Export Article

Open AccessReview
Pharmaceuticals 2017, 10(2), 34; doi:10.3390/ph10020034

Pathophysiological Significance of Dermatan Sulfate Proteoglycans Revealed by Human Genetic Disorders

1
Department of Pathobiochemistry, Faculty of Pharmacy, Meijo University, 150 Yagotoyama, Tempaku-ku, Nagoya 468-8503, Japan
2
Center for Medical Genetics, Shinshu University Hospital, 3-1-1 Asahi, Matsumoto, Nagano 390-8621, Japan
*
Authors to whom correspondence should be addressed.
Academic Editor: Barbara Mulloy
Received: 22 February 2017 / Revised: 22 March 2017 / Accepted: 24 March 2017 / Published: 27 March 2017
(This article belongs to the Special Issue Glycosaminoglycans and Proteoglycans)
View Full-Text   |   Download PDF [1294 KB, uploaded 28 March 2017]   |  

Abstract

The indispensable roles of dermatan sulfate-proteoglycans (DS-PGs) have been demonstrated in various biological events including construction of the extracellular matrix and cell signaling through interactions with collagen and transforming growth factor-β, respectively. Defects in the core proteins of DS-PGs such as decorin and biglycan cause congenital stromal dystrophy of the cornea, spondyloepimetaphyseal dysplasia, and Meester-Loeys syndrome. Furthermore, mutations in human genes encoding the glycosyltransferases, epimerases, and sulfotransferases responsible for the biosynthesis of DS chains cause connective tissue disorders including Ehlers-Danlos syndrome and spondyloepimetaphyseal dysplasia with joint laxity characterized by skin hyperextensibility, joint hypermobility, and tissue fragility, and by severe skeletal disorders such as kyphoscoliosis, short trunk, dislocation, and joint laxity. Glycobiological approaches revealed that mutations in DS-biosynthetic enzymes cause reductions in enzymatic activities and in the amount of synthesized DS and also disrupt the formation of collagen bundles. This review focused on the growing number of glycobiological studies on recently reported genetic diseases caused by defects in the biosynthesis of DS and DS-PGs. View Full-Text
Keywords: biglycan; carbohydrate sulfotransferase 14; decorin; chondroitin sulfate; dermatan sulfate; dermatan sulfate epimerase; dermatan 4-O-sulfotransferase; Ehlers-Danlos syndrome; glycosaminoglycan; proteoglycan; spondyloepimetaphyseal dysplasia. biglycan; carbohydrate sulfotransferase 14; decorin; chondroitin sulfate; dermatan sulfate; dermatan sulfate epimerase; dermatan 4-O-sulfotransferase; Ehlers-Danlos syndrome; glycosaminoglycan; proteoglycan; spondyloepimetaphyseal dysplasia.
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Mizumoto, S.; Kosho, T.; Yamada, S.; Sugahara, K. Pathophysiological Significance of Dermatan Sulfate Proteoglycans Revealed by Human Genetic Disorders. Pharmaceuticals 2017, 10, 34.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top